-
Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future direction
Author: Dong, Weikai; Song, Qifeng; Wang, Qiang
Journal: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1093/ehjcvp/pvag012
-
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting syste
Author: Xia, Huang; Shi, Lei; Luo, Shuimei; Sun, Zequn; Quan, Mengru; Xiao, Huazhen; Chen, Yu; Lin, Jing
Journal: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2026; Vol. , Issue , pp. -. DOI: 10.1093/ehjcvp/pvag006
-
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registr
Author: Lam, Steven Ho Man; Romiti, Giulio Francesco; Corica, Bernadette; Bucci, Tommaso; Olshansky, Brian; Chao, Tze-Fan; Huisman, Menno, V; Lip, Gregory Y. H
Journal: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1093/ehjcvp/pvaf031
-
Potential bias in observational PCSK9 inhibitor stud
Author: Blais, Joseph Edgar; Wong, Angel Y. S
Journal: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2025; Vol. , Issue , pp. -. DOI: 10.1093/ehjcvp/pvaf041
